Form 4: Praxis Precision Medicines Executive Lauren Mastrocola Reports Stock Transaction
SEC Form 4 Filing
Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, reports the disposal of 40 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- On February 12, 2025, Lauren Mastrocola, Principal Accounting Officer of Praxis Precision Medicines, disposed of 40 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations related to the vesting of previously reported restricted stock units.
- The shares were disposed of at a price of $85.4 per share.
- Following the transaction, Mastrocola directly owns 10,441.656 shares of Praxis Precision Medicines common stock.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations, and doesn't indicate a positive or negative outlook for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. This provides transparency to the market.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it involves a small number of shares.
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Date of stock transaction (disposal of shares). |
| 02/14/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.